2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH

The present invention provides triazolone compounds of general formula (I):in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and...

Full description

Saved in:
Bibliographic Details
Main Authors Merz, Claudia, Sheikh, Sherif El, Kröber, Michael, Zimmermann, Katja, Müller, Thomas, Janzer, Andreas, Gradl, Stefan Nikolaus, Nguyen, Duy, Günther, Judith, Stellfeld, Timo, Sykes, David B, Christian, Sven, Niehues, Michael, Ferrara, Steven James, Nising, Carl Friedrich, Eis, Knut, Schäfer, Martina
Format Patent
LanguageEnglish
Published 28.09.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract The present invention provides triazolone compounds of general formula (I):in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
AbstractList The present invention provides triazolone compounds of general formula (I):in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
Author Niehues, Michael
Müller, Thomas
Nising, Carl Friedrich
Günther, Judith
Christian, Sven
Gradl, Stefan Nikolaus
Kröber, Michael
Eis, Knut
Ferrara, Steven James
Merz, Claudia
Stellfeld, Timo
Sheikh, Sherif El
Nguyen, Duy
Schäfer, Martina
Sykes, David B
Janzer, Andreas
Zimmermann, Katja
Author_xml – fullname: Merz, Claudia
– fullname: Sheikh, Sherif El
– fullname: Kröber, Michael
– fullname: Zimmermann, Katja
– fullname: Müller, Thomas
– fullname: Janzer, Andreas
– fullname: Gradl, Stefan Nikolaus
– fullname: Nguyen, Duy
– fullname: Günther, Judith
– fullname: Stellfeld, Timo
– fullname: Sykes, David B
– fullname: Christian, Sven
– fullname: Niehues, Michael
– fullname: Ferrara, Steven James
– fullname: Nising, Carl Friedrich
– fullname: Eis, Knut
– fullname: Schäfer, Martina
BookMark eNrjYmDJy89L5WRwMdIx0THVLSnKLC5NKi7JLCktSU1RMNQBCoMEE6vyc4DqihVKi1PTSnMUEosVMvMyMpMyS_KLihXy0xRcPPxdPHgYWNMSc4pTeaE0N4Oim2uIs4duakF-fGpxQWJyal5qSXxosKGhobGBuYmpk5ExMWoA1n4yrQ
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US11130745B2
GroupedDBID EVB
ID FETCH-epo_espacenet_US11130745B23
IEDL.DBID EVB
IngestDate Fri Jul 19 13:55:46 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US11130745B23
Notes Application Number: US202016996721
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210928&DB=EPODOC&CC=US&NR=11130745B2
ParticipantIDs epo_espacenet_US11130745B2
PublicationCentury 2000
PublicationDate 20210928
PublicationDateYYYYMMDD 2021-09-28
PublicationDate_xml – month: 09
  year: 2021
  text: 20210928
  day: 28
PublicationDecade 2020
PublicationYear 2021
RelatedCompanies THE GENERAL HOSPITAL CORPORATION
BAYER AKTIENGESELLSCHAFT
BAYER PHARMA AKTIENGELLSCHAFT
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
BAYER AKTIENGELLSCHAFT
THE BROAD INSTITUTE, INC
BAYER PHARMA AKTIEGELLSCHAFT
THE BROAD INSTITUTE INC
RelatedCompanies_xml – name: BAYER PHARMA AKTIEGELLSCHAFT
– name: THE BROAD INSTITUTE INC
– name: BAYER PHARMA AKTIENGELLSCHAFT
– name: BAYER AKTIENGELLSCHAFT
– name: BAYER AKTIENGESELLSCHAFT
– name: THE GENERAL HOSPITAL CORPORATION
– name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
– name: THE BROAD INSTITUTE, INC
Score 3.353185
Snippet The present invention provides triazolone compounds of general formula (I):in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210928&DB=EPODOC&locale=&CC=US&NR=11130745B2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MKeqbTkXnhQjSpxVt2q7rQxHatBRh63Cb7G00aYsV6YbtEPz1ntTO-aIvIZzAIQl858vlXABuMyTNvs2FamY8VQ0LoWhjq1pprIs-TQydymjk4agfzozHuTlvwesmFqbOE_pRJ0dERAnEe1Xb69X2EYvVvpXlHc9RtHwIpg5Tmtsx3l9sOlCY6_jjiEWe4nnObKKMnhxZUR3Z0nTRXO_IY7TMs-8_uzIqZfWbUoJD2B2jtqI6glZadGDf21Re68DesPnwxm6DvfIYGO0ZPVOtEJUI9u8f_oRoPRRLYfyJZgztFlmXabZ-I3FJ8uIl57ksp0OWGWFhxMITuAn8qReqOJ3Fz9oXs8l25voptAvUdAbE1IWwtIwbseBGQm2e3FvIK1QTWcxpop9D92893f8GL-BA7qN0iaCDS2hX7-v0Cnm34tf1hn0BwAKGNw
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MKc43nYrOWwTp04ouva0PRVizUnU33CZ7G03aYkW6YTsEf70ntXO-6EsIJ3BIAt_5cjkXgOsYSdO0uVCNmEeqbiEUbWxVKwo0YdJQ16iMRu4PTH-qP8yMWQVe17EwRZ7QjyI5IiJKIN7zwl4vN49YrPCtzG54gqLFnTdxmFLejvH-YtO2wjpOdzRkQ1dxXWc6VgZPjqyojmxpdNBcb1kyO688Oj13ZFTK8jeleHuwPUJtab4PlSitQ81dV16rw06__PDGbom97AAYbepNQ80RlQj27x_-kLSaKJbC4BPNGNotssqiePVGgowk6UvCE1lOhyxiwvwh8w_hyutOXF_F6cx_1j6fjjcz146gmqKmYyCGJoTVirkeCK6H1ObhrYW8QlsiDjgNtRNo_K2n8d_gJdT8Sb83790PHk9hV-6pdI-g7TOo5u-r6Bw5OOcXxeZ9AS9HiSQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=2%2C4%2C5-trisubstituted+1%2C2%2C4-triazolones+useful+as+inhibitors+of+DHODH&rft.inventor=Merz%2C+Claudia&rft.inventor=Sheikh%2C+Sherif+El&rft.inventor=Kr%C3%B6ber%2C+Michael&rft.inventor=Zimmermann%2C+Katja&rft.inventor=M%C3%BCller%2C+Thomas&rft.inventor=Janzer%2C+Andreas&rft.inventor=Gradl%2C+Stefan+Nikolaus&rft.inventor=Nguyen%2C+Duy&rft.inventor=G%C3%BCnther%2C+Judith&rft.inventor=Stellfeld%2C+Timo&rft.inventor=Sykes%2C+David+B&rft.inventor=Christian%2C+Sven&rft.inventor=Niehues%2C+Michael&rft.inventor=Ferrara%2C+Steven+James&rft.inventor=Nising%2C+Carl+Friedrich&rft.inventor=Eis%2C+Knut&rft.inventor=Sch%C3%A4fer%2C+Martina&rft.date=2021-09-28&rft.externalDBID=B2&rft.externalDocID=US11130745B2